Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -2006.87% is 3052% below its 3-year average of -63.68%, around the middle of its 3-year range (-4356.16%–0.00%).
46.42% below its 12-month average of -1370.62%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -636.78%.
NET PROFIT MARGIN
-2006.87%
NET PROFIT MARGIN AVG TTM
-1370.62%
NET PROFIT MARGIN AVG 3Y
-63.68%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-46.42%
CURRENT VS 3Y AVG
-3051.59%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-573291.43%
vs the sector median at left
Bullfrog AI Holdings, Inc. Common Stock
Market Cap
$12.78M
Net Profit Margin
-2006.87%
TTM Avg
-1370.62%
3Y Avg
-63.68%
5Y Avg
0.00%
Market Cap
$12.58M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$12.48M
Net Profit Margin
-804.37%
TTM Avg
-21365.78%
3Y Avg
-11028.80%
5Y Avg
-7352.54%
Market Cap
$12.44M
Net Profit Margin
-48.94%
TTM Avg
-40.16%
3Y Avg
-67.25%
5Y Avg
-58.35%
Market Cap
$13.11M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$13.20M
Net Profit Margin
-651.27%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$13.30M
Net Profit Margin
-3972.87%
TTM Avg
-1209.50%
3Y Avg
-3598.61%
5Y Avg
-2399.08%
Market Cap
$12.17M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $12.78M | -2006.87% | -1370.62% | -63.68% | 0.00% |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.58M | 0.00% | 0.00% | 0.00% | 0.00% |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | -804.37% | -21365.78% | -11028.80% | -7352.54% |
| Cytosorbents Corporation (CTSO)vs › | $12.44M | -48.94% | -40.16% | -67.25% | -58.35% |
| Passage Bio, Inc. (PASG)vs › | $13.11M | 0.00% | 0.00% | 0.00% | 0.00% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | -651.27% | 0.00% | 0.00% | 0.00% |
| Optimi Health Corp. (OPTH)vs › | $13.30M | -3972.87% | -1209.50% | -3598.61% | -2399.08% |
| IN8bio, Inc. (INAB)vs › | $13.33M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lantern Pharma Inc. (LTRN)vs › | $12.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.06M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-5652.4%
Net Profit Margin
-2006.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -636.78% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | -1860.16% |
| 2025-06-30 | -4356.16% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | -1927.66% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | -6955.18% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |